Tokyo - Delayed Quote JPY

Nxera Pharma Co., Ltd. (4565.T)

876.00
-2.00
(-0.23%)
At close: May 9 at 3:30:00 PM GMT+9
Currency in JPY All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
28,835,000
28,835,000
12,766,000
15,569,000
17,712,000
Cost of Revenue
7,616,000
7,616,000
3,102,000
926,000
933,000
Gross Profit
21,219,000
21,219,000
9,664,000
14,643,000
16,779,000
Operating Expense
26,642,000
26,642,000
19,190,000
11,207,000
13,004,000
Operating Income
-5,423,000
-5,423,000
-9,526,000
3,436,000
3,775,000
Net Non Operating Interest Income Expense
761,000
761,000
-1,154,000
-93,000
-3,598,000
Pretax Income
-4,662,000
-4,662,000
-10,680,000
1,078,000
433,000
Tax Provision
176,000
176,000
-3,487,000
696,000
-584,000
Net Income Common Stockholders
-4,838,000
-4,838,000
-7,193,000
382,000
1,017,000
Diluted NI Available to Com Stockholders
-4,838,000
-4,838,000
-7,193,000
382,000
1,017,000
Basic EPS
-53.92
-53.92
-87.18
4.68
12.53
Diluted EPS
-53.92
-53.92
-87.18
4.63
12.40
Basic Average Shares
89,732.03
89,732.03
82,516.51
81,785.01
81,187.31
Diluted Average Shares
89,732.03
89,732.03
82,516.51
82,590.44
82,590.44
Total Operating Income as Reported
-5,423,000
-5,423,000
-9,526,000
3,436,000
3,775,000
Total Expenses
34,258,000
34,258,000
22,292,000
12,133,000
13,937,000
Net Income from Continuing & Discontinued Operation
-4,838,000
-4,838,000
-7,193,000
382,000
1,017,000
Normalized Income
-4,838,000
-4,838,000
-7,193,000
1,792,048
874,077.20
Interest Income
1,544,000
1,544,000
1,341,000
663,000
199,000
Interest Expense
783,000
783,000
2,495,000
756,000
3,797,000
Net Interest Income
761,000
761,000
-1,154,000
-93,000
-3,598,000
EBIT
-3,879,000
-3,879,000
-8,185,000
1,834,000
4,230,000
EBITDA
105,000
105,000
-5,707,000
3,179,000
5,508,000
Reconciled Cost of Revenue
7,616,000
7,616,000
3,102,000
926,000
933,000
Reconciled Depreciation
3,984,000
3,984,000
2,478,000
1,345,000
1,278,000
Net Income from Continuing Operation Net Minority Interest
-4,838,000
-4,838,000
-7,193,000
382,000
1,017,000
Total Unusual Items Excluding Goodwill
--
--
0
-1,836,000
206,000
Total Unusual Items
--
--
0
-1,836,000
206,000
Normalized EBITDA
105,000
105,000
-5,707,000
5,015,000
5,302,000
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
0
0
0
-425,952
63,077.20
12/31/2021 - 7/29/2004

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

130A.T VERITAS IN SILICO INC
667.00
+0.91%
 
7774.T Japan Tissue Engineering Co., Ltd.
627.00
+2.79%
 
344860.KQ INNOGENE Co.,Ltd.
2,165.00
+11.94%
 
203400.KQ ABION Inc.
6,040.00
+0.50%
 
000504.SZ Landfar Bio-medicine Co., Ltd
6.65
+5.06%
 
475960.KQ TOMOCUBE
20,200.00
-2.18%
 
086900.KQ Medy-Tox Inc.
181,300.00
-0.17%
 
CONCORDBIO.BO Concord Biotech Limited
1,539.65
+0.39%
 
347850.KQ D&D Pharmatech
73,400.00
-2.52%
 
302440.KS SK bioscience Co.,Ltd.
40,300.00
+0.25%